FPA144: Preliminary Phase I data

Preliminary data from 27 patients with solid tumors in the dose-escalation Part 1 of an open-label, U.S. Phase I trial showed that doses of up to 15 mg/kg IV FPA144 every 2 weeks were well tolerated w...